These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6851822)

  • 1. Continuous imaging of regional blood flow in peripheral vascular disease using Krypton-81m: effect of Ketanserin, a new selective serotonin antagonist.
    Gerritsen HA; Perquin JW; de Smet HL; Troost FA; Kotora OV
    Diagn Imaging; 1983; 52(2-3):85-92. PubMed ID: 6851822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ketanserin in the treatment of ischemic disease of the lower extremities].
    Gerová Z; Brimichová E; Dzúrik R
    Cas Lek Cesk; 1985 Jul; 124(30):938-41. PubMed ID: 3161617
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experiences with bencyclane in peripheral disorders of arterial blood supply].
    Alánt O; Horváth N
    Arzneimittelforschung; 1970 Oct; 20(10):Suppl 10a:1403+. PubMed ID: 5536654
    [No Abstract]   [Full Text] [Related]  

  • 4. Intra arterial ketanserin in peripheral vascular disease.
    Boas RA
    Angiology; 1986 Apr; 37(4):267-71. PubMed ID: 2940946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
    Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A
    Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dynamic study of venous return from the lower extremities by means of krypton-81 m perfusion].
    Zicot M; Guillaume M; Redote R
    J Mal Vasc; 1985; 10(1):3-9. PubMed ID: 3981072
    [No Abstract]   [Full Text] [Related]  

  • 9. [Medical therapy of obliterating arteriopathies].
    Schwarz D
    Minerva Med; 1969 Oct; 60(87):4335-44. PubMed ID: 4242895
    [No Abstract]   [Full Text] [Related]  

  • 10. Peripheral arterial disease diagnosed with high-count-rate radionuclide arteriography.
    Oshima M; Ijima H; Kohda Y; Kuramoto K; Kikuchi Y; Wada M; Akisada M
    Radiology; 1984 Jul; 152(1):161-6. PubMed ID: 6233631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases.
    Park K; Itoh H; Yamahara K; Sone M; Miyashita K; Oyamada N; Sawada N; Taura D; Inuzuka M; Sonoyama T; Tsujimoto H; Fukunaga Y; Tamura N; Nakao K
    Endocrinology; 2008 Feb; 149(2):483-91. PubMed ID: 17991722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rheographic study of the activity of some vasoactive drugs on peripheral arterial circulation].
    Capitanucci P; Martinelli M; De Gregorio M
    Minerva Cardioangiol; 1968 Nov; 16(11):1074-82. PubMed ID: 5707452
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of regional cerebral blood flow by continuous carotid infusion of krypton-81m.
    Fazio F; Nardini M; Fieschi C; Forli C
    J Nucl Med; 1977 Oct; 18(10):962-6. PubMed ID: 903479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of bencyclane in obliterative arterial diseases].
    Kusztos D
    Arzneimittelforschung; 1970 Oct; 20(10):Suppl 10a:1419+. PubMed ID: 5536658
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous imaging of regional myocardial blood flow in dogs using krypton-81m.
    Turner JH; Selwyn AP; Jones T; Evans TR; Raphael MJ; Lavender JP
    Cardiovasc Res; 1976 May; 10(3):398-404. PubMed ID: 954025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research on the activity of propaxoline in vasculopathic syndromes. II. Peripheral rheographic studies of the lower extremities].
    Rottini E; Martinelli M; Capitanucci P; De Gregorio M
    Boll Soc Ital Biol Sper; 1967 Aug; 43(16):970-2. PubMed ID: 6073457
    [No Abstract]   [Full Text] [Related]  

  • 17. Ketanserin: a selective serotonin antagonist.
    Lancet; 1982 Oct; 2(8303):859. PubMed ID: 6126719
    [No Abstract]   [Full Text] [Related]  

  • 18. [The clinical significance of serotonin antagonists].
    Regenthal R; Voigt H
    Z Gesamte Inn Med; 1989 Sep; 44(17):504-8. PubMed ID: 2686226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A method of insulin therapy of chronic obliterating arteriopathies. Clinical results and etiopathogenetic considerations].
    Bonessa C; Cremonini L
    Minerva Med; 1966 Jul; 57(44):2027-40. PubMed ID: 5942708
    [No Abstract]   [Full Text] [Related]  

  • 20. Arteriography of the extremities, with an analysis of the occlusive diseases of the arteries in the lower extremities.
    Suzuki S
    Am J Roentgenol Radium Ther Nucl Med; 1969 Jun; 106(2):400-17. PubMed ID: 5789504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.